1. Volume 384, Issue 9957, Pages 1849-1858 (November 2014)
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial 
Adeel Shahzad, MRCP, Ian Kemp, BA, Christine Mars, Dip HE, Keith Wilson, Claire Roome, MBBS, Rob Cooper, MRCP, Mohammed Andron, MD, Clare Appleby, PhD, Mike Fisher, PhD, Aleem Khand, MD, Babu Kunadian, MD, Joseph D Mills, MD, John L Morris, MD, William L Morrison, MD, Shahzad Munir, MD, Nick D Palmer, MD, Raphael A Perry, DM, David R Ramsdale, MD, Periaswamy Velavan, MD, Dr Rod H Stables, DM 
The Lancet 
Volume 384, Issue 9957, Pages (November 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
PPCI=primary percutaneous coronary intervention. STEMI=ST-elevation myocardial infarction. DAPT=dual antiplatelet therapy. LMWH=low molecular weight heparin.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2 Event curves for the primary outcomes
(A) Primary efficacy outcome (combination of death, cerebrovascular accident, reinfarction, and unplanned target lesion revascularisation), censored for the first event. (B) Primary safety outcome (major bleeding), censored for the first event.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3 Subgroup analyses for primary composite outcome at 28 days
*Procedures completed exclusively via radial access (radial group) versus all other cases (femoral group). †Patients receiving oral hypoglycaemic or insulin therapy. ‡Left ventricular ejection fraction <55% in surviving patients after index event.
The Lancet  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions